Abstracts tagged "lymphocytes"

Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium
T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Anna Patrick¹, Tashawna Esmond ², David Flaherty ², Thomas Brent Graham ², Susan Thompson ³ and Thomas Aune ¹, ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²Vanderbilt University Medical Center, Nashville, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children. Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
Abstract Number: 610 • 2019 ACR/ARP Annual Meeting
Ankylosing Spondylitis-associated Killer Immunoglobin-like Receptors Are Strongly Expressed on γδ T Cells
Micah Lefton¹, Nihaarika Sharma ¹ and Joerg Ermann ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: The mechanism underlying the association between ankylosing spondylitis (AS) and HLA-B27 is still unknown. One of the hypotheses involves the interaction of HLA-B27 homodimers…
Abstract Number: 2519 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE
Daniel Strasser ¹, Virginie Sippel ¹, Ursula Grieder ¹, Andrea Kieninger-Graefitsch ², Gabin Pierlot ¹, Hervé Farine ¹, Paulina Kulig ¹, Geoffroy Bourquin ¹, Marcel Keller ¹, Peter Groenen ¹, Marten Trendelenburg ² and Mark Murphy¹, ¹Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ²University Hospital Basel, Basel, Switzerland
Background/Purpose: SLE is an autoimmune disease driven by autoreactive T and B lymphocytes. Lymphocytes infiltrate self-antigen expressing tissues, in which tertiary lymphoid structures are often…
Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Amira El Gerby ¹, Abeer Abdelati ², Hanaa Donia ³ and Nouran Eshak⁴, ¹Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, ²alexandria university, alexandria, Egypt, ³Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, ⁴Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX
Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 1110 • 2018 ACR/ARHP Annual Meeting
Characterization of CD20+ T Cells in Patients with Systemic Sclerosis
Monica D'Orazio¹, Elisabeth Fliesser², Florentine Moazedi-Fürst³, Martin Stradner⁴, Sonja Kielhauser³, Johannes Fessler⁵ and Hans-Peter Brezinschek¹, ¹Internal Medicine/Division of Rheumatoloy and Immunology, Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ²Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ⁴Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵Department of Neurology, Harvard Medical School, Boston, MA
Background/Purpose: Recently, it has been demonstrated that a subset of T cells expresses the B-cell marker CD20. It has been postulated that in rheumatoid arthritis…
Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting
Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
Satoshi Kubo¹, Shingo Nakayamada¹, Yusuke Miyazaki¹, Maiko Yoshikawa², Hiroko Yoshinari³, Shigeru Iwata⁴, Kentaro Hanami², Shunsuke Fukuyo³, Ippei Miyagawa⁵, Kazuhisa Nakano¹ and Yoshiya Tanaka⁶, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…
Abstract Number: 2586 • 2018 ACR/ARHP Annual Meeting
Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
Gerd R. Burmester¹, William FC Rigby², Ernest Choy³, Peter Nash⁴, Kevin Winthrop⁵, Philip J. Mease⁶, Pamela Young⁷, Thijs Hendrikx⁷, Cunshan Wang⁸, Sujatha Menon⁸ and Daniela Graham⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴University of Queensland, Brisbane, Australia, ⁵Oregon Health and Science University, Portland, OR, ⁶Swedish Medical Center and University of Washington, Seattle, WA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function, and homeostasis signal…
Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting
Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Imtiyaz Hossain, Mederbek Matmusaev and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Bohdan P. Harvey¹, Li Li¹, Mark Konrad¹, Heather Knight¹, Susan Westmoreland², Melanie Ruzek¹ and Zehra Kaymakcalan¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
Abstract Number: 1427 • 2017 ACR/ARHP Annual Meeting
Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib
Gerd R. Burmester¹, Zoltan Szekanecz², Pinaki Biswas³, Sriram Krishnaswami⁴, Christopher F Mojcik³, Hernan Valdez³, Jamie Geier³ and Sander Strengholt⁵, ¹Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²University of Debrecen Faculty of Medicine, Debrecen, Hungary, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Lymphopenia is a frequent feature of RA,1 and RA medications may also…
Abstract Number: 2125 • 2017 ACR/ARHP Annual Meeting
Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study
Okinori Murata¹, Atsuko Kudo² and Katsuya Suzuki³, ¹Department of Pulmonary medicine, Hachinohe Red Cross Hospital, Hachinohe, Japan, ²Hachinohe Red Cross Hospital, Hachinohe, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan
Background/Purpose: Sarcoidosis is a systemic granulomatous disease that can affect multiple organs, and in particular lung involvements are common and found in more than 90%…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
Abstract Number: 1825 • 2016 ACR/ARHP Annual Meeting
the Non-Coding Genome and the Genetics of Systemic Lupus
Joyce Hui-Yuen¹, Lisha Zhu², Lai Ping Wong³, Kaiyu Jiang⁴, Yanmin Chen⁴, Tao Liu⁵ and James Jarvis⁶, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Pediatrics, The University at Buffalo, Buffalo, NY, ⁵Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁶Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, complex disease believed to be triggered by gene-environment interactions. While we have made considerable progress in investigation…
Abstract Number: 2569 • 2016 ACR/ARHP Annual Meeting
Restoration of Decreased Lymphocyte Counts and the Shift to Th1 and Effector Memory CD8+T Cell Subsets Associate with Spontaneous Regression of Lympho-Proliferative Disorders Developed in RA Patients Treated with Methotrexate
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹, Koichi Amano², Michihide Tokuhira³ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ³Department of Hematology, Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose: Methods: Forty-three RA patients complicated with LPD were identified and 76 control patients were selected. Among the 43 LPD patients, 28 were regressive and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].